INVITROCUE LIMITED - Announcements

Currently unlisted. Add to my watchlist

Invitrocue Limited is engaged in research and experimental development on biotechnology,... Invitrocue Limited is engaged in research and experimental development on biotechnology, life and medical science. The Company offers a three dimension (3D) cell-based scaffolding technology, which mimics a human for Tropical Diseases to investigate the lifecycle of Plasmodium cynomolgi (monkey malaria) and helps in evaluating new drug targets to malaria infection using in vitro hepatocyte culture systems. It is engaged in developing non-small cell lung cancer organoids and for drug testing programs using approved drugs. It is also engaged in range of activities, including in vitro cell-based assays, patient-derived organoids, digital pathology and medical imaging, while providing access to industry networks. It also offers an in vitro screening of experimental drug compounds for anti-leishmanial activity. It intends to develop an in vitro 3D perfused liver model to expedite and facilitate new application notes in infectious liver diseases.More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

IVQ	De-listing, Unmarketable Sale and Directors Resignation	PRICE SENSITIVE	26/02/21	303.76KB	Share
IVQ	Appendix 4C - quarterly	PRICE SENSITIVE	01/02/21	454.77KB	Share
IVQ	Appendix 4C - quarterly	PRICE SENSITIVE	02/11/20	455.67KB	Share
IVQ	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/20	376.5KB	Share
IVQ	4C Commentaries and Management Updates	PRICE SENSITIVE	01/05/20	338.99KB	Share
IVQ	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/20	375.36KB	Share
IVQ	Onco-PDO cancer test successfully registered for CE Mark	PRICE SENSITIVE	21/04/20	80.96KB	Share
IVQ	Joint Venture MOU for Brazilian and Latin American market	PRICE SENSITIVE	11/02/20	242.44KB	Share
IVQ	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/20	375.16KB	Share
IVQ	Response to ASX Query	PRICE SENSITIVE	30/12/19	760.53KB	Share
IVQ	Significant investment and joint venture with a fund	PRICE SENSITIVE	06/12/19	619.29KB	Share
IVQ	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/19	278.94KB	Share
IVQ	Appendix 4E and Annual Report	PRICE SENSITIVE	02/10/19	3.24MB	Share
IVQ	S203D notice	PRICE SENSITIVE	12/09/19	112.92KB	Share
IVQ	S203D notices	PRICE SENSITIVE	06/09/19	212.03KB	Share
IVQ	Suspension from Official Quotation - Annual Listing Fee	PRICE SENSITIVE	22/08/19	440.19KB	Share
IVQ	Suspension from Official Quotation	PRICE SENSITIVE	12/08/19	71.73KB	Share
IVQ	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/19	259.55KB	Share
IVQ	Quarterly Appendix 4C and Business updates	PRICE SENSITIVE	30/04/19	316.63KB	Share
IVQ	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/19	1.47MB	Share
IVQ	*IVQ joint venture with ASTAR scientist Dr. Chen Qingfeng**	PRICE SENSITIVE	11/02/19	579.69KB	Share
IVQ	Quarterly Appendix 4C and Business updates	PRICE SENSITIVE	31/01/19	860.58KB	Share
IVQ	IVQ signs agreement to develop Onco-PDO breast cancer models	PRICE SENSITIVE	23/01/19	574.48KB	Share
IVQ	IVQ roll-out of Onco-PDO services in Germany	PRICE SENSITIVE	18/01/19	583.76KB	Share
IVQ	Quarterly Appendix 4C and Business updates	PRICE SENSITIVE	31/10/18	921.2KB	Share
IVQ	Preliminary Final Report	PRICE SENSITIVE	31/08/18	863.75KB	Share
IVQ	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/18	697.91KB	Share
IVQ	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/18	347.69KB	Share
IVQ	IVQ launches Personalised Cancer Screening Service Onco-PDO	PRICE SENSITIVE	13/04/18	461.01KB	Share
IVQ	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/18	1.2MB	Share
IVQ	Grant from Northern Ireland to commercialize Onco-PDO	PRICE SENSITIVE	26/02/18	458.63KB	Share
IVQ	Appendix 4C & quarterly business update	PRICE SENSITIVE	31/01/18	1021.05KB	Share
IVQ	IVQ successfully grows liver cancer organoids	PRICE SENSITIVE	18/01/18	249.24KB	Share
IVQ	Proposed issue of securities	PRICE SENSITIVE	10/11/17	196.71KB	Share
IVQ	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/17	280.82KB	Share
IVQ	Preliminary Final Report	PRICE SENSITIVE	31/08/17	787.92KB	Share
IVQ	IVQ receives award from Singapore government IP office	PRICE SENSITIVE	29/08/17	448.01KB	Share
IVQ	Appendix 4C quarterly and Business Update	PRICE SENSITIVE	31/07/17	743.79KB	Share
IVQ	Establishment of joint lab with Genome Institute Singapore	PRICE SENSITIVE	20/07/17	463.99KB	Share
IVQ	Updates to IVQ's collaboration with the Garvan Institute	PRICE SENSITIVE	03/07/17	569.79KB	Share
IVQ	Proposed issue of securities	PRICE SENSITIVE	29/06/17	197.33KB	Share
IVQ	IVQ expands into in-vitro skin and wound healing assays	PRICE SENSITIVE	22/05/17	300.92KB	Share
IVQ	Response to ASX Appendix 4C Query	PRICE SENSITIVE	11/05/17	716.19KB	Share
IVQ	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/17	279.48KB	Share
IVQ	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/17	285.33KB	Share
IVQ	Collaboration with the Garvan Institute of Medical Research	PRICE SENSITIVE	23/02/17	297.1KB	Share
IVQ	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/17	698.67KB	Share
IVQ	Appendix 4C - quarterly-IVQ.AX	PRICE SENSITIVE	31/10/16	278.76KB	Share
IVQ	Research Collaboration with Genome Institute of Singapore-IVQ.AX	PRICE SENSITIVE	24/10/16	303.6KB	Share
IVQ	Addendum to Preliminary Final Report-IVQ.AX	PRICE SENSITIVE	08/09/16	230.62KB	Share
IVQ	*IVQ Awarded Singapore's ASTAR Tender-IVQ.AX**	PRICE SENSITIVE	05/09/16	228.47KB	Share
IVQ	Preliminary Final Report-IVQ.AX	PRICE SENSITIVE	31/08/16	732.84KB	Share
IVQ	IVQ signs strategic partnership agreement with QIAGEN Suzhou-IVQ.AX	PRICE SENSITIVE	22/08/16	319.62KB	Share
IVQ	IVQ announces new program focused on Hepatitis B virus-IVQ.AX	PRICE SENSITIVE	28/07/16	229.66KB	Share
IVQ	Appendix 4C - quarterly-IVQ.AX	PRICE SENSITIVE	28/07/16	503.54KB	Share
IVQ	IVQ commences Pancreatic Toxicity Assay development-IVQ.AX	PRICE SENSITIVE	12/07/16	240.39KB	Share
IVQ	IVQ Announces Malaria Initiative-IVQ.AX	PRICE SENSITIVE	16/05/16	173.3KB	Share
IVQ	IVQ Expands 3D Cell-based Platform for Oncology-IVQ.AX	PRICE SENSITIVE	12/05/16	65.33KB	Share
IVQ	Appendix 4C - quarterly-IVQ.AX	PRICE SENSITIVE	27/04/16	423.55KB	Share
IVQ	Agreement with London School of Hygiene & Tropical Medicine	PRICE SENSITIVE	09/03/16	167.18KB	Share
IVQ	Operations update	PRICE SENSITIVE	07/03/16	157.52KB	Share
IVQ	Half Yearly Report and Accounts	PRICE SENSITIVE	29/02/16	344.76KB	Share
IVQ	Operations update	PRICE SENSITIVE	16/02/16	566.57KB	Share
IVQ	Operations update	PRICE SENSITIVE	08/02/16	173.67KB	Share

IVQ De-listing, Unmarketable Sale and Directors Resignation
26/02/21	PRICE SENSITIVE	303.76KB	Share
IVQ Appendix 4C - quarterly
01/02/21	PRICE SENSITIVE	454.77KB	Share
IVQ Appendix 4C - quarterly
02/11/20	PRICE SENSITIVE	455.67KB	Share
IVQ Appendix 4C - quarterly
31/07/20	PRICE SENSITIVE	376.5KB	Share
IVQ 4C Commentaries and Management Updates
01/05/20	PRICE SENSITIVE	338.99KB	Share
IVQ Appendix 4C - quarterly
29/04/20	PRICE SENSITIVE	375.36KB	Share
IVQ Onco-PDO cancer test successfully registered for CE Mark
21/04/20	PRICE SENSITIVE	80.96KB	Share
IVQ Joint Venture MOU for Brazilian and Latin American market
11/02/20	PRICE SENSITIVE	242.44KB	Share
IVQ Appendix 4C - quarterly
30/01/20	PRICE SENSITIVE	375.16KB	Share
IVQ Response to ASX Query
30/12/19	PRICE SENSITIVE	760.53KB	Share
IVQ Significant investment and joint venture with a fund
06/12/19	PRICE SENSITIVE	619.29KB	Share
IVQ Appendix 4C - quarterly
31/10/19	PRICE SENSITIVE	278.94KB	Share
IVQ Appendix 4E and Annual Report
02/10/19	PRICE SENSITIVE	3.24MB	Share
IVQ S203D notice
12/09/19	PRICE SENSITIVE	112.92KB	Share
IVQ S203D notices
06/09/19	PRICE SENSITIVE	212.03KB	Share
IVQ Suspension from Official Quotation - Annual Listing Fee
22/08/19	PRICE SENSITIVE	440.19KB	Share
IVQ Suspension from Official Quotation
12/08/19	PRICE SENSITIVE	71.73KB	Share
IVQ Appendix 4C - quarterly
31/07/19	PRICE SENSITIVE	259.55KB	Share
IVQ Quarterly Appendix 4C and Business updates
30/04/19	PRICE SENSITIVE	316.63KB	Share
IVQ Half Yearly Report and Accounts
28/02/19	PRICE SENSITIVE	1.47MB	Share
IVQ *IVQ joint venture with ASTAR scientist Dr. Chen Qingfeng**
11/02/19	PRICE SENSITIVE	579.69KB	Share
IVQ Quarterly Appendix 4C and Business updates
31/01/19	PRICE SENSITIVE	860.58KB	Share
IVQ IVQ signs agreement to develop Onco-PDO breast cancer models
23/01/19	PRICE SENSITIVE	574.48KB	Share
IVQ IVQ roll-out of Onco-PDO services in Germany
18/01/19	PRICE SENSITIVE	583.76KB	Share
IVQ Quarterly Appendix 4C and Business updates
31/10/18	PRICE SENSITIVE	921.2KB	Share
IVQ Preliminary Final Report
31/08/18	PRICE SENSITIVE	863.75KB	Share
IVQ Appendix 4C - quarterly
31/07/18	PRICE SENSITIVE	697.91KB	Share
IVQ Appendix 4C - quarterly
30/04/18	PRICE SENSITIVE	347.69KB	Share
IVQ IVQ launches Personalised Cancer Screening Service Onco-PDO
13/04/18	PRICE SENSITIVE	461.01KB	Share
IVQ Half Yearly Report and Accounts
28/02/18	PRICE SENSITIVE	1.2MB	Share
IVQ Grant from Northern Ireland to commercialize Onco-PDO
26/02/18	PRICE SENSITIVE	458.63KB	Share
IVQ Appendix 4C & quarterly business update
31/01/18	PRICE SENSITIVE	1021.05KB	Share
IVQ IVQ successfully grows liver cancer organoids
18/01/18	PRICE SENSITIVE	249.24KB	Share
IVQ Proposed issue of securities
10/11/17	PRICE SENSITIVE	196.71KB	Share
IVQ Appendix 4C - quarterly
30/10/17	PRICE SENSITIVE	280.82KB	Share
IVQ Preliminary Final Report
31/08/17	PRICE SENSITIVE	787.92KB	Share
IVQ IVQ receives award from Singapore government IP office
29/08/17	PRICE SENSITIVE	448.01KB	Share
IVQ Appendix 4C quarterly and Business Update
31/07/17	PRICE SENSITIVE	743.79KB	Share
IVQ Establishment of joint lab with Genome Institute Singapore
20/07/17	PRICE SENSITIVE	463.99KB	Share
IVQ Updates to IVQ's collaboration with the Garvan Institute
03/07/17	PRICE SENSITIVE	569.79KB	Share
IVQ Proposed issue of securities
29/06/17	PRICE SENSITIVE	197.33KB	Share
IVQ IVQ expands into in-vitro skin and wound healing assays
22/05/17	PRICE SENSITIVE	300.92KB	Share
IVQ Response to ASX Appendix 4C Query
11/05/17	PRICE SENSITIVE	716.19KB	Share
IVQ Appendix 4C - quarterly
28/04/17	PRICE SENSITIVE	279.48KB	Share
IVQ Half Yearly Report and Accounts
28/02/17	PRICE SENSITIVE	285.33KB	Share
IVQ Collaboration with the Garvan Institute of Medical Research
23/02/17	PRICE SENSITIVE	297.1KB	Share
IVQ Appendix 4C - quarterly
30/01/17	PRICE SENSITIVE	698.67KB	Share
IVQ Appendix 4C - quarterly-IVQ.AX
31/10/16	PRICE SENSITIVE	278.76KB	Share
IVQ Research Collaboration with Genome Institute of Singapore-IVQ.AX
24/10/16	PRICE SENSITIVE	303.6KB	Share
IVQ Addendum to Preliminary Final Report-IVQ.AX
08/09/16	PRICE SENSITIVE	230.62KB	Share
IVQ *IVQ Awarded Singapore's ASTAR Tender-IVQ.AX**
05/09/16	PRICE SENSITIVE	228.47KB	Share
IVQ Preliminary Final Report-IVQ.AX
31/08/16	PRICE SENSITIVE	732.84KB	Share
IVQ IVQ signs strategic partnership agreement with QIAGEN Suzhou-IVQ.AX
22/08/16	PRICE SENSITIVE	319.62KB	Share
IVQ IVQ announces new program focused on Hepatitis B virus-IVQ.AX
28/07/16	PRICE SENSITIVE	229.66KB	Share
IVQ Appendix 4C - quarterly-IVQ.AX
28/07/16	PRICE SENSITIVE	503.54KB	Share
IVQ IVQ commences Pancreatic Toxicity Assay development-IVQ.AX
12/07/16	PRICE SENSITIVE	240.39KB	Share
IVQ IVQ Announces Malaria Initiative-IVQ.AX
16/05/16	PRICE SENSITIVE	173.3KB	Share
IVQ IVQ Expands 3D Cell-based Platform for Oncology-IVQ.AX
12/05/16	PRICE SENSITIVE	65.33KB	Share
IVQ Appendix 4C - quarterly-IVQ.AX
27/04/16	PRICE SENSITIVE	423.55KB	Share
IVQ Agreement with London School of Hygiene & Tropical Medicine
09/03/16	PRICE SENSITIVE	167.18KB	Share
IVQ Operations update
07/03/16	PRICE SENSITIVE	157.52KB	Share
IVQ Half Yearly Report and Accounts
29/02/16	PRICE SENSITIVE	344.76KB	Share
IVQ Operations update
16/02/16	PRICE SENSITIVE	566.57KB	Share
IVQ Operations update
08/02/16	PRICE SENSITIVE	173.67KB	Share

REFRESH

INVITROCUE LIMITED - Announcements

Announcements

Top Stories